First and only TIGIT/TGF-β dual-targeting antibody fusion protein of Akeso demonstrated promise in preclinical results published at ESMO ...Middle East

HONG KONG, Sept, 13, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso"), a China-based biopharmaceutical company focusing on the development and commercialization of innovative therapeutic antibodies for Oncology & Immunology, published encouraging preclinical results in poster...

Hence then, the article about first and only tigit tgf b dual targeting antibody fusion protein of akeso demonstrated promise in preclinical results published at esmo was published today ( Tuesday 13/09/2022 - 09:16 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( First and only TIGIT/TGF-β dual-targeting antibody fusion protein of Akeso demonstrated promise in preclinical results published at ESMO )

Also on site :

• BTS Dominates YouTube’s Global, U.S. Charts
• Quest Global est reconnue comme un leader dans le rapport ISG Provider Lens® 2025 Report for Manufacturing Industry Services and Solutions
• ‘America’s Culinary Cup’ Season 1: Who Went Home Tonight? (Night 5 Elimination)